Adcetris Market Report 2026

Adcetris Market Overview

• The Adcetris market growth in the historic period has been driven by advances in monoclonal antibody research, rising incidence of hodgkin lymphoma • Market expansion is supported by expansion into additional indications, increasing oncology biologics investment • Growth Driver: Impact Of Rising Cancer Prevalence On The Growth Of The Adcetris Market • Market Trend: Advancements In Antibody-Drug Conjugates (ADCs) And Drug Delivery Systems With Key Developments And Market Strategies In Oncology • North America was the largest region in 2025 and Asia Pacific is the fastest growing region.

What Is Covered Under Adcetris Market?

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that targets CD30, a protein found on the surface of certain cancer cells, including those in Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It combines a monoclonal antibody with a cytotoxic agent, monomethyl auristatin E (MMAE), to deliver targeted chemotherapy directly to the cancer cells, improving efficacy and reducing off-target side effects. The main types of adcetris are powder and liquid. Adcetris is supplied as a sterile, white to off-white lyophilized powder in single-dose vials before administration, healthcare professionals reconstitute this powder with a specific amount of sterile water to prepare it for intravenous infusion. The various indication includes hodgkin lymphoma, systemic anaplastic large-cell lymphoma, cutaneous T-cell lymphoma, and others. These are used in various applications such as hospitals, drug stores, and others.

What Is The Adcetris Market Growth Forecast?

The adcetris market size is expected to see strong growth in the next few years. It will grow to $2.12 million in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to expansion into additional indications, increasing oncology biologics investment, growth in personalized medicine adoption, rising healthcare expenditure on cancer, improved adc manufacturing scalability. Major trends in the forecast period include expanded use of antibody drug conjugates in oncology, growing preference for targeted cancer therapies, rising combination therapy adoption, increased focus on rare lymphoma treatments, improved clinical outcomes in cd30-positive cancers.

Global Adcetris Market Segmentation

1) By Type: Powder, Liquid 2) By Indication: Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Cutaneous T-Cell Lymphoma, Other Indication 3) By Application: Hospital, Drugs Store, Other Applications

What Is The Driver Of The Adcetris Market?

The rising prevalence of cancer is expected to propel the growth of the adcetris market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising prevalence of cancer is due to lifestyle choices such as poor diet and lack of physical activity, increased exposure to environmental pollutants, and advances in diagnostic techniques. Adcetris offers significant benefits for cancer patients by specifically targeting and binding to CD30-positive cancer cells, thereby delivering potent cytotoxic agents directly to the tumor site, improving treatment efficacy, reducing systemic side effects, and offering a promising option for patients with certain types of Hodgkin lymphoma and other CD30-expressing malignancies. For instance, in January 2023, according to the American Cancer Society, a US-based non-profit cancer advocacy organization, the number of cancer cases increased to 1,958,310 in 2023, and 609,820 cancer deaths in the United States. Therefore, the rising prevalence of cancer drives the adcetris industry.

Key Players In The Global Adcetris Market

Major companies operating in the adcetris market are Takeda Pharmaceutical Company Limited, Seagen Inc.

Global Adcetris Market Trends and Insights

The key trend in the adcetris market is focusing on developing improved antibody-drug conjugates (ADCs) and enhanced drug delivery solutions such as combination therapies to improve the therapeutic efficacy, reduce side effects, and target cancer cells more precisely. Combination therapies refer to treatment strategies that use two or more therapeutic agents with different mechanisms of action, often synergistically, to enhance efficacy, minimize resistance, and improve patient outcomes while potentially reducing adverse effects compared to monotherapy. For instance, in October 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, received the European Commission (EC) approval for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the treatment of adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma. This is an antibody-drug conjugate directed at CD30, a key marker of Hodgkin lymphoma. This trial demonstrated that the combination of ADCETRIS with AVD significantly improved both modified progression-free survival and overall survival rates compared to traditional treatments.

What Are Latest Mergers And Acquisitions In The Adcetris Market?

In January 2024, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. With this acquisition, Pfizer Inc. aims to strengthen its oncology portfolio by integrating Seagen Inc.'s innovative antibody-drug conjugates, including Adcetris, to enhance its cancer treatment offerings, drive growth in targeted therapies, and accelerate its ability to deliver cutting-edge cancer treatments to patients worldwide. Seagen Inc. is a US-based biotechnology company that offers adcetris.

Regional Insights

North America was the largest region in the adcetris market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Adcetris Market?

The adcetris market consists of sales of brentuximab vedotin-based therapies such as antibody-drug conjugates (ADCs), bispecific antibodies, and immune checkpoint inhibitors for the treatment of lymphoma and related cancers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adcetris Market Report 2026?

The adcetris market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adcetris industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.